CINtec^® PLUS Cytology

Cytology: be certain about the presence of a transforming HPV infection

The goal of screening is to avoid misdiagnosis and the over- or under-treatment it causes. While Pap cytology has had a positive impact on HPV and cervical cancer screening over the past 50 years, it is resource-intensive and subject to misinterpretation and missed disease.

CINtec^® PLUS Cytology is a triage test for cervical cancer screening, and the only test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infections. CINtec^® PLUS Cytology objectively identifies transforming HPV infections in women with abnormal Pap cytology results and HPV-positive cervical cancer screening results, allowing laboratory professionals to help physicians be certain they can recommend follow-up for women who will benefit most from colposcopy.

Abnormal cytology can’t hide anymore with CINtec^® PLUS Cytology

Unique dual-biomarker technology makes you certain about the presence of transforming HPV infection.

CINtec^® PLUS Cytology is the only test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 to provide a strong indicator of the presence of transforming HPV infections.

Co-expression of p16 and Ki-67 in the same cell is strongly associated with established high-grade disease.

• Clinicians use screening and triage tests to identify the risk of disease and can manage women based on their level of risk.
• Various combinations of screening and triage tests can result in differences in disease detection and the number of colposcopies required.
• A strategy that results in more disease detection without increasing the colposcopy rate can aid clinicians making decisions that result in improved clinical outcomes and lower healthcare costs.

Additional information, from the same sample collected for HPV DNA or Pap screening, helps ensure women are not lost to follow-up

• CINtec^® PLUS Cytology provides immediate and actionable triage results
  
• Reduces both the number and frequency of follow-up visits required
• Gives women clear answers and certainty in their test results

CINtec^® PLUS Cytology is a triage test for cervical cancer screening

An objective biomarker triage test for ASC-US and LSIL, abnormal Pap cytology screening results

CINtec^® PLUS Cytology identifies underlying transforming HPV infections in women with abnormal Pap cytology results to send the women who will benefit most from colposcopy for follow-up testing.

An objective biomarker triage test with high sensitivity and specificity

cobas^® HPV DNA test with triage using CINtec^® PLUS Cytology detects transformig HPV infections and helps avoid unnecessary colposcopy for women who do not need it immediately.

An objective biomarker test to help triage Pap negative/HPV (+) co-testing results

Improve management of women with Pap cytology negative/HPV (+) results: In co-testing, CINtec^® PLUS Cytology provides immediate and actionable results to help reduce the number of women lost to follow-up testing.

• The test indicates oncogenically transforming HPV infections, and thus eliminates equivocation over morphologic abnormalities that are not pre-cancerous. Very good overall clinical accuracy has been demonstrated in key cervical cancer screening scenarios.
• Overall, p16/Ki-67 dual staining has the potential to significantly reduce the number of women referred for confirmatory colposcopy.

Currently, the CINtec^® PLUS Cytology test is included in guidelines in Ecuador, France, Germany, Hong Kong, Portugal, South Africa, and Spain.

Physicians can more effectively triage and manage patients with CINtec® PLUS Cytology